SecBot SecBot

MLAB

MESA LABORATORIES INC
Nasdaq· Industrial Instruments For Measurement, Display, and Control· Inc. CO· CIK 0000724004 Industrials & Manufacturing
$129.87 +1.21 (+0.94%)
Oct 26 4:00 PM ET · prev $128.66
Market cap
$722.4M
Small cap
Consensus
Buy
75% Buy or better · 8 analysts
Median target
$125.00
−4% · range $125.00–125.00
Next earnings
Nov 5
in 10 days · EPS est. $2.24
1 year
+68.9%
from $76.89 · Oct 27
30 days
−2.3%
from $132.99
52-week range
$70.60–142.23
−9% from high · low Nov 21
Avg volume 20D
94.4K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$215.7K
4 buyers · 4 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 4 bullish · 3 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 7/9 ·Next Earnings date, Nov 5, 2026
Strongest MIXED Mesa Laboratories announced a restructuring program (Item 2.05) on October 13, 2026, to focus its Clinical…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersMIXED

    4 insiders bought $1.4M at an average $96.00. 4 insiders sold $1.6M. Price is 35% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 27 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    6 of 8 rate it Buy or better. Price is above every target.

  • EstimatesRISING

    Current-quarter EPS estimate $1.260 → $2.240 over 90 days. 0 up, 1 down in 30 days.

  • TrendRANGE

    2% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
JACOBS LEVY EQUITY MANAGEMENT, INCDOUBLED130,838$13.0M
WASATCH ADVISORS LPDOUBLED115,668$11.5M
ROYCE & ASSOCIATES LPTRIM113,395$11.3M
FMR LLCDOUBLED88,857$8.8M
D. E. Shaw & Co., Inc.ADD81,755$8.1M
VANGUARD PORTFOLIO MANAGEMENT LLCADD69,350$6.9M
CITADEL ADVISORS LLCDOUBLED35,890$3.6M
Man Group plcDOUBLED24,070$2.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 75% rate it Buy or better
Strong Buy3Buy3Hold2Sell0Strong Sell0
12-month targets · 1 analysts

Price is above the highest target. Median implies −4%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 14, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight

Insider ledger

Form 4
$1.4M
bought · 4 insiders
$1.6M
sold · 4 insiders
+35.3%
vs their $96.00 cost
DateInsiderTypeValue
Sep 9, 2026
Tripeny R Tony
Director
AWARD1,774 sh
Sep 9, 2026
Sullivan John James
Director
AWARD1,774 sh
Sep 9, 2026
Hall Shannon
Director
AWARD1,774 sh
Sep 9, 2026
Ladiwala Shiraz Shabanali
Director
AWARD2,510 sh
Sep 9, 2026
Capone Mark Christopher
Director
AWARD2,423 sh
Aug 15, 2026
Sullivan John James
Director
EXERCISE2,784 sh
Aug 15, 2026
Ladiwala Shiraz Shabanali
Director
EXERCISE3,810 sh
Aug 15, 2026
Hall Shannon
Director
EXERCISE2,784 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
$2.24
EPS estimate, this quarter
+78%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$2.24$2.24–$2.24-17.9%$62.2M
Next Q$2.71$2.71–$2.71-18.6%$66.0M
Current FY$9.95$9.95–$9.95-14.4%$254.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 13, 2026 SEC
Mesa Laboratories announced a restructuring program (Item 2.05) on October 13, 2026, to focus its Clinical Genomics…
8-K — Impact 6/10
Oct 13, 2026 Press
Mesa Laboratories announced a restructuring and savings plan expected to reduce annualized operating costs by ~$9.3M…
Impact 6/10
Oct 13, 2026 Announcement
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Steriliza
Oct 9, 2026 SEC
Wasatch Advisors LP disclosed a new 6.9% passive stake in Mesa Laboratories via Schedule 13G, holding 387,129 common…
SC 13G — Impact 4/10
Sep 9, 2026 Insider
Tripeny R Tony was granted 1,774 shares
Director
Sep 9, 2026 Insider
Sullivan John James was granted 1,774 shares
Director
Sep 9, 2026 Insider
Hall Shannon was granted 1,774 shares
Director
Aug 17, 2026 SEC
A cluster of three MLAB insiders traded on August 13: CEO Siddhartha Kadia bought $800K in open-market shares…
CLUSTER — Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
MLAB Q2 2027 Earnings Scheduled — 2026-11-05
Recent
Oct 13, 2026
Announcement
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration…
Aug 10, 2026
Earnings
Mesa Labs Announces First Quarter Results
LAKEWOOD, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or the “Company”), a global leader in the design…
Aug 10, 2026
Earnings date
MLAB Q1 2027 Earnings Scheduled — 2026-08-10
Aug 3, 2026
Announcement
Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call
LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in…
Aug 3, 2026
Earnings date
MLAB Q1 2027 Earnings Scheduled — 2026-08-03

SecBot reports

12 filings · 4 press releases · 5 bullish · 0 bearish · 3 mixed · 4 neutral
All MLAB filing & press-release reports (16)